While Russia is one of the top producers of both metals, it is not the only source of these metals so it should be fine.
Clinical trial supply especially in Phase 1 and 2 where Clarity's products are in will not need an extensive supply so it shouldn't be a big issue.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.13 |
Change
-0.170(2.70%) |
Mkt cap ! $1.910B | |||
| Open | High | Low | Value | Volume |
| $6.32 | $6.48 | $6.11 | $5.556M | 885.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.20 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |